Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
about
Antiviral oseltamivir is not removed or degraded in normal sewage water treatment: implications for development of resistance by influenza A virusSubstandard/counterfeit antimicrobial drugsOseltamivir Population Pharmacokinetics in the Ferret: Model Application for Pharmacokinetic/Pharmacodynamic Study DesignA randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combinationChemical analysis and transplacental transfer of oseltamivir and oseltamivir carboxylic acid in pregnant ratsEnteric absorption and pharmacokinetics of oseltamivir in critically ill patients with pandemic (H1N1) influenza.Oseltamivir dosing for influenza infection in premature neonates.Lack of pharmacokinetic interaction between the oral anti-influenza prodrug oseltamivir and aspirin.Rapid degradation of oseltamivir phosphate in clinical samples by plasma esterasesDried blood spot UHPLC-MS/MS analysis of oseltamivir and oseltamivircarboxylate--a validated assay for the clinic.Quantitative trace analysis of a broad range of antiviral drugs in poultry muscle using column-switch liquid chromatography coupled to tandem mass spectrometry.Importance of collection tube during clinical studies of oseltamivir.Lack of pharmacokinetic interaction between the oral anti-influenza neuraminidase inhibitor prodrug oseltamivir and antacidsLack of effect of moderate hepatic impairment on the pharmacokinetics of oral oseltamivir and its metabolite oseltamivir carboxylate.Population pharmacokinetics of oseltamivir in non-pregnant and pregnant women.Simple and sensitive assay for quantification of oseltamivir and its active metabolite oseltamivir carboxylate in human plasma using high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry: improved appliOseltamivir pharmacokinetics, dosing, and resistance among children aged <2 years with influenza.Low penetration of oseltamivir and its carboxylate into cerebrospinal fluid in healthy Japanese and Caucasian volunteersDetermination of oseltamivir quality by colorimetric and liquid chromatographic methods.Oseltamivir dosing in premature infants.Simultaneous quantification of prodrug oseltamivir and its metabolite oseltamivir carboxylate in human plasma by LC-MS/MS to support a bioequivalence study.
P2860
Q21144425-4E851AE7-FB81-4153-A314-A9F3811BA9C7Q27009319-F5948C9A-3A96-4F8E-80E5-250D3CAF2A4FQ27317735-2C223DA4-C11E-4BEF-A249-E0A9C47D12F5Q28471710-4E3B14B8-AA4C-43E2-BEC8-04772AB050B1Q28484222-159D1939-02FC-409A-8C90-A786FA2E2A8DQ30385708-BA2BC157-B247-4865-9BB6-973F9E3CC336Q33996464-37D812EA-7501-478C-8A1E-C7AD7C4CCDC4Q34109232-B27E28A6-DD71-43DB-9B27-EED77502710EQ35023358-CAC7DAA7-BE93-4129-92BD-85CB13AA7F7FQ35059104-04FC5489-067D-47D2-8DD8-28778D893CC4Q35685732-82B5840B-3476-4162-9D9A-46485998ECC1Q35759115-FD846654-1564-40EE-A5D5-1BB1395DEB2AQ35804050-39F6C7D4-C2DD-497A-85DE-013BEFB8BC53Q35827008-4911329E-C0C3-49CF-9D3E-C568DC721089Q36243630-5E7BACBB-AADC-4990-8A6F-8FEE81A21B6CQ36395220-D30AB417-BC9F-489C-AAF9-EAB60892594BQ36584645-2554D5E3-8635-4956-99DA-CE8DCC4CCB25Q36932915-896F795B-B8E6-4BBF-BCB4-FF70ADB944A3Q41836261-53037583-63FD-4212-8773-494081E09CD5Q41890159-4C5813DB-D2C1-4DF8-ACD0-299752A5C8F0Q50196742-CE0FC53A-A9C6-4FCA-B2C6-412FB0BEFCD5
P2860
Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Development of a high-performa ...... n and animal plasma and urine.
@ast
Development of a high-performa ...... n and animal plasma and urine.
@en
type
label
Development of a high-performa ...... n and animal plasma and urine.
@ast
Development of a high-performa ...... n and animal plasma and urine.
@en
prefLabel
Development of a high-performa ...... n and animal plasma and urine.
@ast
Development of a high-performa ...... n and animal plasma and urine.
@en
P2093
P1476
Development of a high-performa ...... an and animal plasma and urine
@en
P2093
B Wiltshire
H Wiltshire
P304
P356
10.1016/S0378-4347(00)00300-5
P577
2000-08-01T00:00:00Z